AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) shares were up 5.9% during mid-day trading on Tuesday . The stock traded as high as $66.58 and last traded at $65.9640. Approximately 321,154 shares were traded during trading, a decline of 57% from the average session volume of 749,931 shares. The stock had previously closed at $62.31.
Analysts Set New Price Targets
A number of brokerages have recently commented on ANAB. Zacks Research downgraded shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Barclays upped their price target on shares of AnaptysBio from $63.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th. Leerink Partners set a $90.00 price target on AnaptysBio in a report on Friday, May 15th. UBS Group raised their price objective on AnaptysBio from $60.00 to $76.00 and gave the company a “buy” rating in a research report on Wednesday, May 13th. Finally, HC Wainwright initiated coverage on AnaptysBio in a research note on Wednesday, June 10th. They set a “buy” rating and a $95.00 price objective on the stock. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, AnaptysBio presently has an average rating of “Moderate Buy” and a consensus price target of $81.82.
Get Our Latest Stock Report on ANAB
AnaptysBio Stock Up 0.0%
AnaptysBio (NASDAQ:ANAB – Get Free Report) last announced its earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($1.20). The business had revenue of $25.56 million during the quarter, compared to the consensus estimate of $18.86 million. As a group, equities research analysts expect that AnaptysBio, Inc. will post -1.35 earnings per share for the current fiscal year.
AnaptysBio declared that its Board of Directors has authorized a stock buyback program on Friday, March 27th that authorizes the company to buyback $100,000.00 billion in shares. This buyback authorization authorizes the biotechnology company to purchase up to 5,352,316.2% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.
Hedge Funds Weigh In On AnaptysBio
A number of hedge funds have recently bought and sold shares of ANAB. Smartleaf Asset Management LLC raised its stake in AnaptysBio by 5,864.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 821 shares in the last quarter. Larson Financial Group LLC grew its position in shares of AnaptysBio by 54.6% in the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 473 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of AnaptysBio by 175.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 1,377 shares during the last quarter. Osaic Holdings Inc. increased its holdings in shares of AnaptysBio by 11,630.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 2,326 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of AnaptysBio by 24.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 263 shares in the last quarter.
About AnaptysBio
AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.
The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.
Featured Stories
- Five stocks we like better than AnaptysBio
- Catching the AI Wave: DigitalOcean Reels in AI Whales
- Rivian’s 75 Million-Share Offering Turns the R2 Growth Story Into a Dilution Test
- Sony Is Going All-Digital—But Investors Should Watch This Instead
- Scotiabank Sees a New Growth Story for Cloudflare
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.
